GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.63 No.1-2 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/2303
|
タイトル: | アンジオテンシンⅡ刺激による血管平滑筋細胞の遊走に対するSrc阻害とMAPキナーゼ阻害効果の比較 |
その他のタイトル: | COMPARISON OF THE EFFECTS OF SRC INHIBITION AND MITOGEN-ACTIVATED PROTEIN KINASE INHIBITION ON THE MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS STIMULATED BY ANGIOTENSIN Ⅱ |
著者: | 趙, 晶 京谷, 陽司 伊藤, 都裕 長山, 功佑 小澤, 健太郎![](/dspace/image/metalink/link_ja.gif) 吉栖, 正典![](/dspace/image/metalink/link_ja.gif) |
キーワード: | Angiotensin Ⅱ 血管平滑筋 細胞運動 siRNA src-Family Kinases MAP Kinases 遺伝子サイレンシング |
発行日: | 2012年4月30日 |
出版者: | 奈良医学会 奈良県立医科大学 |
引用: | Journal of Nara Medical Association Vol.63 No.1-2 p.25-35 |
抄録: | Angiotensin Ⅱ (AⅡ) plays an important role in various cardiovascular diseases associated with vascular smooth muscle cell (VSMC) growth and migration. In our previous study, we investigated the effect of olmesartan, an angiotensin Ⅱ receptor blocker, on AⅡ-induced Src tyrosine kinase, extracellular signal-regulated kinases 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) activation and rat aortic smooth muscle cell (RASMC) migration. We found that olmesartan inhibited AⅡ-induced ERK1/2 and JNK activation at lower concentrations. On the other hand, PP2, a Src tyrosine kinase inhibitor, also inhibited AⅡ-induced ERK1/2 and JNK activation, but its effect on ERK1/2 was less pronounced than that of olmesartan. However, both olmesartan and PP2 potently inhibited AⅡ-induced RASMC migration. In the present study, we investigated the involvement of Src on AⅡ-induced migration of RASMC using Src siRNA for gene silencing. Src siRNA was successfully introduced into RASMC using transfection procedures. We found that the inhibitory effect of Src siRNA on AⅡ-induced JNK activation was more potent than on ERK1/2 activation in RASMC. In addition, Src siRNA effectively inhibited AⅡ-induced RASMC migration to an extent similar to PP2. From these findings, it was inferred that direct inhibition of Src may be an effective option for VSMC growth and migration. Pharmacological or genetic inhibition of Src may be a strategy that can be used in addition to renin-angiotensin blockade for cardiovascular diseases involving AⅡ, such as hypertension and atherosclerosis. |
URI: | http://hdl.handle.net/10564/2303 |
ISSN: | 13450069 |
出現コレクション: | Vol.63 No.1-2
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|